Research on Amyotrophic Lateral Sclerosis (ALS) Opportunity Analyzer Size and Share 2018

Most up-to-date research on "OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018" to its huge collection of research reports.

Amyotrophic lateral sclerosis (ALS) is a rare, but fatal, motor neuron disease (MND) characterized by axonal degeneration and progressive loss of motor neurons. ALS affects both the upper (brain to spinal cord) and lower (brain stem to muscle tissue) motor neurons, gradually reducing a patients ability to initiate and control muscle movement. Muscle atrophy, starting in the periphery (arms and legs), ultimately leads to complete paralysis after several years of progressive worsening of muscle strength. Respiratory failure is the most common cause of death, as smooth muscle function becomes affected when the disease is in its final stages. The progressively degenerative course of the condition is a great burden for both patients and caregivers, as well as for society. ALS usually affects people age =40 years, and has a worldwide incidence of about two cases per 100,000 population, and a prevalence ranging between four and seven cases per 100,000.

Browse Detail Report With TOC @


Key Questions Answered
  • How does the patent expiration of Rilutek effect the ALS market?
  • The pipeline consists of novel but unproven mechanisms of action in ALS. Which of these therapies will attain high sales revenues during 2013-2018, and in which markets?
  • How large an impact will Methycobal and Edaravone have on the ALS market in Japan? What do key opinion leaders think of these treatment approaches?
  • What effects will advancing diagnostic and disease modeling capabilities have on drug development?
  • What regulatory efforts are likely to affect drug development in the markets researched? Which is the largest growth market globally?

Key Findings
  • Country-specific orphan drug and rare disease policy heavily influences development opportunities in the 7MM.
  • Discovery of potential symptomatic and disease-modifying therapies in early stage clinical development is challenged by the absence of ALS biomarkers and disease staging that can demonstrate a patients response to treatment.
  • Pharmaceutical products for ALS will face growing competition from gene and stem cell-based therapies.
  • Advances in animal modeling are expected to have a significant impact on ALS drug development.

Browse Reports in Pharmaceutical @

  • Overview of ALS, including etiology and pathophysiology, general symptoms, quality of life, country-specific treatment recommendations and epidemiologic data.
  • Annualized ALS market revenue, annual cost of treatment and usage patterns from 2013 and forecast for five years to 2018.
  • Key topics covered include unmet needs analysis, research and development strategies, pipeline assessment, and pipeline valuation analysis for the ALS market.
  • Pipeline valuation analysis: clinical and commercial benchmarking of AB Sciences AB-1010 (masitinib), Cytokinetics CK-2017357 (tirasemtiv), Mitsubishi Tanabes Radicut (edaravone), Eisais Methycobal (mecobalamin), and Orphazyme ApS arimoclomol.
  • Assessment of the current and future market competition in the global ALS drug market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the ALS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ALS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global ALS market from 2013-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Related Report
Bristol-Myers Squibb Company - Product Pipeline Review - 2014
Bristol-Myers Squibb Company - Product Pipeline Review - 2014 Summary Global Markets Directs, Bristol-Myers Squibb Company - Product Pipeline Review - 2014, provides an overview of the Bristol-Myers Squibb Companys pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bristol-Myers Squibb Companys,...

Merck & Co., Inc. - Product Pipeline Review - 2014
Merck & Co., Inc. - Product Pipeline Review - 2014 Summary Global Markets Directs, Merck & Co., Inc. - Product Pipeline Review - 2014, provides an overview of the Merck & Co., Inc.s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Merck & Co., Inc.s, complete with comparative analysis at various...

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact: